Fresenius SE & Co KGaA (XTER:FRE)
€ 33.2 -0.28 (-0.84%) Market Cap: 18.70 Bil Enterprise Value: 29.09 Bil PE Ratio: 0 PB Ratio: 1.04 GF Score: 61/100

Fresenius SE & Co KGaA at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 01:20PM GMT
Release Date Price: €38.85 (-2.94%)
David James Adlington
JPMorgan Chase & Co, Research Division - Head of Medical Technology and Services Equity Research

Good morning, good afternoon, everybody. This is David Adlington from the JPMorgan med tech team in Europe. It's my pleasure this morning to start off with Stephan Sturm, CEO of Fresenius SE.

Stephan is going to make some, I think, brief introductory comments, and then we're going to head into Q&A. Thanks for joining us today, Stephan, and over to you for those comments.

Stephan Sturm
Fresenius SE & Co. KGaA - CEO, President & Chairman of Management Board - Fresenius Management SE

Thank you, David. Thank you. Good morning, everyone. Your interest in Fresenius is appreciated, as always. Happy new year, even though 2021 has already started.

Very briefly, we have had a different and a difficult 2020 by normal Fresenius standards. We had a good Q1 but had a trough in the second quarter where, in particular, the lack of elective surgery at our hospital businesses were felt. We were saying at the time that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot